A Deeper Look into Checkpoint Inhibitors in the Management of MSI-High Colorectal Cancer: What Does the Latest Evidence Have to Say?

A continuing medical education activity sponsored by NAMCP and AAMCN.

The Promise of Immunotherapy in the Management of Gastrointestinal Cancers: What Does Managed Care Need to Know About Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors is a 3-part live webinar series that will provide attendees with the latest information in the management of GI Cancers?

This is Part 2 of the series focusing on Checkpoint Inhibitors in the Management of Colorectal Cancer

This activity is an archive from the webinar held March 15, 2019

This activity is valid from April 1, 2019 to April 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard.

Upon completion of this activity, participants will be able to:

  • Evaluate the safety and efficacy data and evidence for the use of anti–PD-1 immunotherapy in MSI-High metastatic colorectal cancer alone or in combination with other agents, and describe recent clinical data

  • Examine the current guideline recommendations for MSI-H/dMMR testing, as well as implications for treatment selection for patients with metastatic MSI-H/dMMR colorectal cancer

  • Explore strategies for the prevention & optimal management of immune-related adverse effects in metastatic colorectal cancer

Faculty: Minsig Choi, MD
Co-Director, GI Oncology Management Team
Director, Gastronintestinal Medical Oncology
Stony Brook Cancer Center


Dr. Choi is on the speaker’s bureau for Amgen, Bayer, Bristol-Myers Squibb, and Merck. He has received research funding from Merck and Ipsen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Co

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue